Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-08-28
2007-08-28
O'Hara, Eileen B. (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S145100, C424S139100, C424S158100, C530S387100, C530S389100, C530S389200
Reexamination Certificate
active
10627499
ABSTRACT:
Methods are described for treating inflammatory bowel disease in animals, including humans. Specific avian polyclonal antibodies directed to proinflammatory cytokines (such as IL-6 and TNF) are shown to have a beneficial effect in animal models predictive of human therapy for the treatment of colitis, including Crohn's disease.
REFERENCES:
patent: 4477432 (1984-10-01), Hardie
patent: 4676982 (1987-06-01), Hassig
patent: 4677064 (1987-06-01), Mark et al.
patent: 4748018 (1988-05-01), Stolle et al.
patent: 4870163 (1989-09-01), Rubin et al.
patent: 5080895 (1992-01-01), Tokoro
patent: 5334380 (1994-08-01), Kilbourn et al.
patent: 5385901 (1995-01-01), Kaplan et al.
patent: 5420253 (1995-05-01), Emery et al.
patent: 5436154 (1995-07-01), Barbanti et al.
patent: 5487984 (1996-01-01), Allet et al.
patent: 5604231 (1997-02-01), Smith et al.
patent: 5614540 (1997-03-01), Christensen
patent: 5654407 (1997-08-01), Boyle et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 5672347 (1997-09-01), Aggarwal et al.
patent: 5698195 (1997-12-01), Le et al.
patent: 5707622 (1998-01-01), Fong et al.
patent: 5753228 (1998-05-01), Sterling et al.
patent: 5772999 (1998-06-01), Greenblatt et al.
patent: 5795967 (1998-08-01), Aggarwal et al.
patent: 6395273 (2002-05-01), Kink et al.
patent: 6663864 (2003-12-01), Kink et al.
patent: 0 155 549 (1991-03-01), None
patent: WO92/07585 (1992-05-01), None
patent: WO96/33204 (1996-10-01), None
patent: WO97/15327 (1997-05-01), None
patent: WO98/14209 (1998-04-01), None
Eigler et al., Immunol. Today, Oct. 1997, vol. 18(10), pp. 487-492.
Woolley and Landon, J. Immunol. Methods, 1995, vol. 178, pp. 253-265.
Otto et al., Clin. Diagn. Lab. Immunol., Jul. 1997, vol. 4(4), pp. 487-490.
Polson et al., Immunol. Commun., 1980, 9(5): 475-493. (Abstract).
Hawkey C. J., in Inflammatory Bowel Diseases, R. N. Allan (eds), New York, Churchill Livingstone, 1997, pp. 521-534.
Worledge et al., 2000, Dig. Dis. and Sci., 45(12):2298-2305.
Polson et al., “Antibodies to Proteins from Yolk of Immunized Hens,”Immunol. Comm., 9:495-514 (1980).
Okayasu et al.,“A Novel Method in the Induction of Reliable Experimental Acute and Chronic Ulcerative Colitis in Mice,”Gastroenterology, 98:694-702 (1990).
Kojouharoff et al.,“Neutralization of tumour necrosis facto (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice,”Clin. Exp.Immunology, 107:353-358 (1997).
Olson et al., “Antiserum to Tumor Necrosis Factor and failure to Prevent Murine Colitis,”J. Pediatric Gatroenterology and Nutrition21: 410-418 (1995).
Stack et al. , “The Effects of CDP571, An Engineered Human IgG∝4 Anti-TNF∝ Antibody in Crohn's Disease”,Gastroenterology, 110:A1018 (1996).
Rutgeerts et al.,“Retreatment with Anti-TNF-∝ Chimeric Antibody (cA2) Effectively maintains cA3-Induced remission in Crohn's Disease,”Gastroenterology112:A1078 (1997).
Van Dullemen et al.,“Treatment of Crohn's Disease with Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2),”Gastroenterology109:129-138 (1995).
Targan et al.,“A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor ∝ for Crohn's Disease,”New England Journal of Medicine, 337:1029-1035 (1997).
Plevy et al.,“A Role for TNF-∝ and Mucosal T Helper-I Cytokines in the Pathogenesis of Crohn's Disease,”Journal of Immunology,6277-6282 (1997).
Sartor,“Current Concepts of the Etiology and Pathogenesis of Ulcerative Colitis and Crohn's Disease,”Inflammatory Bowel Disease, 24:475-507 (1995).
Sartor,“Pathogenesis and Immune Mechanisms of Chronic Inflammatory Bowl Diseases,”Gastroenterology, 92:5S-11S (1997).
Robinson, “Optimizing Therapy for Inflammatory Bowel Disease,”American Journal of Gastroenterology, 92:12-17 (1997).
Targan and Shanahan, “Pseudomembranous Colitis and Clostrridium Difficle Infection,” Inflammatory Bowel Disease from Bench to Bench, 51:743-755 (1994).
Ogorek and Fisher, “Differentiation Between Chrohn's Disease and Ulcerative Colitis,” inInflammatory Bowel Disease, Katz, ed., 78:1249-1257 (1994).
Cameron,“Anti-TNF-∝ treatments set to mop up in rheumatoid arthritis,”Research and Development, pp. 9-10 (1998).
Elliott et al., “Randomised double-blind comparison of chimeric monoclonal antibody to tomour necrosis facto ∝ (cA2) versus placebo in rheumatoid arthritis,”Lancet, 344:1105-1110 (1994).
Elliott et al., “Repeated therapy with monoclonal antibody to tomour necrosis factor ∝ (cA2) in patients with rheumatoid arthritis,”Lancet344:1125-1127 (1994).
Gibson, “Inflammatory Bowel Disease Current Concepts in Pathogenesis and Therapy,”Clin. Immunother., 2(2):135-160 (1994).
Bell and Wallace, “Inflammatory Bowel Disorders Current and Future Drugs that Modulate Adhesion Molecules,”Biodrugs, 7(4):273-284 (1997).
Opal et al., “Potential Hazards of Combination Immunotherapy in the Treatment of Experimental Septic Shock,”J. Infect. Dis., 173:1415-1421(1996).
Russell et al., “Combined Inhibition of Interleukin-1 and Tumor Necrosis Factor in Rodent Endotoxemia: Improved Survival and Organ Function,”J. Infect. Dis.171:1528-1538(1995).
Levine et al., “Intravenous Immunoglobulin Therapy for Active, Extensive and Medically Refractory Idiopathic Ulcerative or Crohn's Colitis”Am J Gastroenterol, 87:91-100 (1992).
Neurath et al., “Predominant Pathogenic role of Tumor Necrosis Factor in Experimental Colitis in Mice,”Eur J Immunol27:1743-1750 (1997).
Neurath et al., “Antibodies to Interleukin 12 Abrogate Established Experimental Colitis in mice,”J Exp Med182:1281-1290 (1995).
Feldmann et al., “Cytokine Expression and Networks in Rheumatoid Arthritis: Rationale for Anti-TNFanpha Antibody Therapy and its Mechanism of Action,”J Inflammation47:90-96 (1996).
Reimund et al., “Increased production of tumor necrosis factor-alpha, interleukin-I-beta and interleukin-6 by morphologically normal interstinal biopsies from patients with Crohn's disease”Gut39:684-689 (1996).
Duchmann et al., “Tolerance toweards resistant intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12,”Eur J Immunol26:934-938 (1996).
Tsubokura et al., “Oral administration of antibodies as prophylaxis and therapy inCampylobacter jejuni-infected chickens,”Clin Exp Immunol108:451-455 (1997).
Nicholls et al., “Cytokines in stools of children with inflammatory bowel disease or infective diarrrhoea,”J Clin Path46:757-760 (1993).
Tjellström et al., “Oral immunoglobulin treatment in Crohn's disease,”Acta Paediatr86:221-223 (1997).
Rubalteli et al., “Prevention of necrotizing enterocolitis in neonates at risk by oral administration of monomeric IgG,”Dev Pharmacol Ther17:138-143 (1991).
Armstrong et al., “Tumor necrosis factor and inflammatory bowel disease,”British Journal of Surgery84:1051-1058 (1997).
Monteleone et al., “Interleukin 12 (IL-12) is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells (LPMCs),”Gastroenterology112:1169-1178 (1997).
Starnes et al., “Anti-IL-6 monoclonal antibodies protect against lethalEscherichia coliinfection and lethal tumor necrosis factor-alpha challenge in mice”J Immuno12:4185-4191 (1990).
Doherty et al., “Evidence for IFN-gama as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha”J Immuno5:1666-1670 (1992).
Manthey et al., “The role of cytokines in host responses to endotoxin”Reviews in Med Microbio3:72-79 (1992).
Dalekos, et al., “High concentrations of soluable interleukin-2 receptors and interleukin-6 in active ulcerative cel
Kink John A.
Stafford Douglas C.
Worledge Katherine L.
Medlen & Carroll LLP
O'Hara Eileen B.
Promega Corporation
Xie Xiaozhen
LandOfFree
Antibodies to cytokines in the prevention and treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to cytokines in the prevention and treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to cytokines in the prevention and treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3840258